LRRTM1 Inhibitors
LRRTM1 inhibitors comprise a diverse array of chemicals that exert their influence on LRRTM1 expression and function either directly or indirectly through intricate cellular pathways. A common theme among these inhibitors is their ability to modulate key signaling cascades, thereby regulating LRRTM1 in various cellular contexts. One noteworthy group includes AMP-activated protein kinase (AMPK) activators such as A769662. By altering cellular energy status through AMPK activation, these chemicals indirectly impact LRRTM1, demonstrating the interconnectedness between energy homeostasis and LRRTM1 expression. Another set of LRRTM1 inhibitors involves the disruption of mitogen-activated protein kinase (MAPK) pathways. Compounds like U0126, PD0325901, and SB203580 selectively target components of the MAPK/ERK and p38 MAPK pathways. Through inhibition of these pathways, LRRTM1 expression and function are modulated, highlighting the pivotal role of MAPK signaling in LRRTM1 regulation. Additionally, the phosphoinositide 3-kinase (PI3K) inhibitors LY294002 and Wortmannin indirectly influence LRRTM1 by disrupting the PI3K/AKT pathway, showcasing the intricate interplay between PI3K signaling and LRRTM1.
The mTOR inhibitor Rapamycin and the selective AKT kinase inhibitor AZD5363 represent another class of LRRTM1 inhibitors acting through the PI3K/AKT/mTOR pathway. By modulating mTOR signaling, Rapamycin indirectly impacts LRRTM1, illustrating the importance of mTOR-related cellular processes in LRRTM1 regulation. Similarly, AZD5363 targets AKT, resulting in downstream changes that influence LRRTM1 expression and function. These inhibitors collectively emphasize the intricate network of cellular pathways governing LRRTM1 dynamics. Bromodomain and extraterminal (BET) inhibitors like JQ1 introduce an epigenetic dimension to LRRTM1 regulation. Through the modulation of BET family proteins, JQ1 induces epigenetic changes that impact LRRTM1 expression and function, offering an indirect yet potent avenue for LRRTM1 inhibition. Additionally, BRAF inhibitor LGX818 highlights the significance of the MAPK/ERK pathway in LRRTM1 regulation, further expanding the repertoire of LRRTM1 inhibitors. Lastly, pan-class I PI3K inhibitor BKM120 reinforces the role of the PI3K/AKT pathway in LRRTM1 modulation. By affecting PI3K-mediated signaling events, BKM120 induces downstream changes that intricately regulate LRRTM1 expression and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A potent AMP-activated protein kinase (AMPK) activator that indirectly influences LRRTM1 by modulating cellular energy status, impacting downstream AMPK-regulated pathways, and subsequently altering LRRTM1 expression and function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective p38 mitogen-activated protein kinase (MAPK) inhibitor that indirectly affects LRRTM1 by disrupting the p38 MAPK pathway, which has connections with LRRTM1 signaling, leading to a downregulation of LRRTM1 expression and functional modulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A potent and selective c-Jun N-terminal kinase (JNK) inhibitor that indirectly modulates LRRTM1 by interfering with the JNK signaling pathway, subsequently impacting LRRTM1 expression and function through the disruption of downstream JNK-related processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that indirectly influences LRRTM1 by targeting the PI3K/AKT pathway. This leads to alterations in downstream signaling cascades, ultimately affecting LRRTM1 expression and function through the modulation of AKT-related processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An irreversible inhibitor of PI3K, acting similarly to LY294002, indirectly impacting LRRTM1 through the PI3K/AKT pathway, resulting in changes to LRRTM1 expression and function by altering AKT-mediated cellular processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that indirectly affects LRRTM1 by modulating the mTOR signaling pathway. This results in downstream changes impacting LRRTM1 expression and function through the regulation of mTOR-related cellular processes. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
A selective AKT kinase inhibitor that indirectly modulates LRRTM1 by disrupting the PI3K/AKT pathway. The downstream consequences of AKT inhibition lead to alterations in LRRTM1 expression and function through the modulation of AKT-related cellular processes. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
A bromodomain and extraterminal (BET) inhibitor that indirectly influences LRRTM1 by targeting the BET family proteins. This results in epigenetic changes impacting LRRTM1 expression and function, providing an indirect avenue for LRRTM1 regulation. | ||||||
BKM120 | 944396-07-0 | sc-364437 sc-364437A sc-364437B sc-364437C | 5 mg 10 mg 25 mg 50 mg | $176.00 $235.00 $281.00 $339.00 | 9 | |
A pan-class I PI3K inhibitor that indirectly influences LRRTM1 by disrupting the PI3K/AKT pathway. The downstream consequences of PI3K inhibition lead to alterations in LRRTM1 expression and function through the modulation of AKT-related cellular processes. | ||||||